- Home
- QBTS vs CHRS Comparison
QBTS vs CHRS Comparison
Compare QBTS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QBTS | CHRS |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | QBTS | CHRS |
|---|---|---|
| Price | $26.73 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $31.50 | $4.02 |
| AVG Volume (30 Days) | ★ 29.4M | 959.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | $24,144,000.00 | ★ $277,728,000.00 |
| Revenue This Year | $194.34 | N/A |
| Revenue Next Year | $56.23 | $67.29 |
| P/E Ratio | ★ N/A | $2.58 |
| Revenue Growth | ★ 156.20 | 152.07 |
| 52 Week Low | $3.74 | $0.71 |
| 52 Week High | $46.75 | $1.89 |
Technical Indicators
Market Signals| Indicator | QBTS | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 53.23 |
| Support Level | $23.82 | $1.31 |
| Resistance Level | $27.29 | $1.41 |
| Average True Range (ATR) | 2.50 | 0.09 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 72.13 | 77.34 |
Price Performance
Historical ComparisonAbout QBTS D-Wave Quantum Inc.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.